|
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Human Genome Research Institute (NHGRI)http://www.genome.nih.gov/ For Immediate Release: Wednesday, May 31, 2023 CONTACT: Sarah Bates, 301-402-0911,<email:mauresa.pittman@xxxxxxx>
NIH SCIENTISTS FIND TREATMENT FOR RARE GENETIC SKIN DISORDER
Genome sequencing reveals genetic basis for disabling pansclerotic morphea, a severe inflammatory disease
Researchers at the National Institutes of Health and their colleagues have identified genomic variants that cause a rare and severe inflammatory skin disorder, known as disabling pansclerotic morphea, and have found a potential treatment.
Scientists discovered that people with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug that targets an important feedback loop controlled by the STAT4 protein
and significantly improves symptoms in these patients. The results were published in the New England Journal of Medicine. The study was led by researchers at the National Human Genome Research Institute (NHGRI), part of NIH, in collaboration with researchers from the University of California, San Diego (UCSD) and the University of Pittsburgh. Researchers from
the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases, both part of NIH, also participated in the study. Only a handful of patients have been diagnosed with disabling pansclerotic morphea, a disorder first described in the medical literature around 100 years ago. The disorder causes severe skin lesions and poor wound healing, leading to deep
scarring of all layers of the skin and muscles. The muscles eventually harden and break down while the joints stiffen, leading to reduced mobility. Because the disorder is so rare, its genetic cause had not been identified until now.
“Researchers previously thought that this disorder was caused by the immune system attacking the skin,” said Sarah Blackstone, a predoctoral fellow within NHGRI's Inflammatory Disease Section, a medical student at the University of South
Dakota and co-first author of the study. “However, we found that this is an oversimplification, and that both skin and the immune system play an active role in disabling pansclerotic morphea.”
The researchers used genome sequencing to study four individuals with disabling pansclerotic morphea and found that all four have genomic variants in the STAT4 gene. The STAT4 gene encodes a type of protein that helps turn genes on and
off, known as a transcription
https://www.genome.gov/genetics-glossary/Transcription factor. The STAT4 protein not only plays a role in fighting infections but also controls important aspects of wound-healing in the skin.
The scientists found that the STAT4 genomic variants result in an overactive STAT4 protein in these four patients, creating a positive feedback loop of inflammation and impaired wound-healing that worsens over time. To stop this harmful
feedback loop, they targeted another protein in the inflammatory pathway that interacts with the STAT4 molecule and is called Janus kinase, also known as JAK. When the researchers treated the patients with a JAK-inhibiting drug called ruxolitinib, the patients’
rashes and ulcers dramatically improved. “So far, there has not been a standard treatment for this disorder because it’s so rare and not well-understood. However, our study gives an important new treatment option for these patients,” said Blackstone.
Existing treatments for disabling pansclerotic morphea are designed to halt the progression of the disorder, but previous therapies have been mostly ineffective, often with severe side effects. People with the disorder typically don’t live
more than 10 years after their diagnosis. The study suggests that ruxolitinib could be an effective treatment for patients with this disorder. Ruxolitinib is part of a broader class of drugs called JAK inhibitors, which are commonly used to treat arthritis, eczema, ulcerative colitis
and other chronic inflammatory diseases. “The findings of this study open doors for JAK inhibitors to be a potential treatment for other inflammatory skin disorders or disorders related to tissue scarring, whether it is scarring of the lungs, liver or bone marrow,” said Dan Kastner,
M.D., Ph.D.< https://www.genome.gov/staff/Dan-Kastner-MD-PhD>, an NIH distinguished investigator, head of NHGRI’s Inflammatory Disease Section and a senior author of the paper.
“We hope to continue studying other molecules in this pathway and how they are altered in patients with disabling pansclerotic morphea and related conditions to find clues to understanding a broader array of more common diseases,” said
Lori Broderick, M.D., Ph.D., a senior author of the paper and an associate professor at UCSD.
The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology
to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at:
https://www.genome.gov/. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit
https://www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ---- REFERENCE: Baghdassarian et al (2023). Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome. New England Journal of Medicine. DOI: 10.1056/NEJMoa2202318 ### This NIH News Release is available online at: To subscribe (or unsubscribe) from NIH News Release mailings, go to http://service.govdelivery.com/service/subscribe.html?code=USNIH_1. If you subscribed via the NIH LISTSERV, go to
https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress. |
